-transparent.png){kind=logo}
Ovalbumin was modified with alpha,beta-poly[(2-hydroxyethyl)-DL-aspartamide] which had been developed as a nontoxic plasma expander. Preadministration of the modified ovalbumin suppressed both primary and secondary anti-ovalbumin IgE responses.
Related Publications
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
August 1980,
Cellular immunology,
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
July 1993,
International journal of immunopharmacology,
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
January 1981,
International archives of allergy and applied immunology,
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
March 1996,
International archives of allergy and immunology,
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
February 2000,
International archives of allergy and immunology,
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
October 1987,
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
January 1984,
International archives of allergy and applied immunology,
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
January 1966,
Antimicrobial agents and chemotherapy,
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
February 1981,
Journal of immunology (Baltimore, Md. : 1950),
M Okada, and
A Matsushima, and
A Katsuhata, and
T Aoyama, and
T Ando, and
Y Inada
January 1978,
The Journal of allergy and clinical immunology,
